Synthes acquisition could boost JNJ
The buy will support efforts to tap growth opportunities in the orthopedics market.
The $19.7 billion acquisition could trigger an upside for the company's stock, which recently has been grappling with a host of lawsuits related to its medical devices and diagnostics franchise.
We have a price estimate for JNJ at $74, implying a premium of nearly 15% to the current market price. We will soon be updating our model to reflect the acquisition.
Synthes acquisition to help boost growth
Synthes has a wide portfolio of medical devices for the orthopedics market, including trauma and spine. The combined J&J/Synthes orthopedic division would have the broadest orthopedic portfolio globally.
We believe the acquisition will lend support to the company's efforts to tap growth opportunities in the orthopedics market. J&J expects the trauma and knee markets to grow 7% and believes spine could rebound to a 5% rate of growth.
Further, the acquisition will also bring the Synthes's vast exposure to fast growing emerging countries including China, India and Russia.
More from Trefis
Copyright © 2014 Microsoft. All rights reserved.
Remy Cointreau says it was 'adversely affected' by China's anti-extravagance policy.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.